Immune Check-point Inhibitor

Xem 1-8 trên 8 kết quả Immune Check-point Inhibitor

Đặc điểm lâm sàng, cận lâm sàng ở bệnh nhân viêm phổi liên quan thuốc ức chế điểm kiểm soát miễn dịch

Bài viết trình bày xác định một số đặc điểm lâm sàng, cận lâm sàng của bệnh nhân viêm phổi liên quan thuốc điều trị ức chế điểm kiểm soát miễn dịch (Immune checkpoint inhibitor – ICI). Nghiên cứu hồi cứu mô tả cắt ngang trên 10 bệnh nhân có biến chứng viêm phổi liên quan ICI trong tổng số 61 ca được điều trị ICI tại khoa Ung bướu – Huyết học, Bệnh viện Đa khoa quốc tế Vinmec Times City năm 2023.

5p virichard 28-03-2024 16 3 Download

Association of advanced age and cancer history with autoimmune disease in melanoma patients: A cross-sectional study

Immune-related adverse events (irAEs) are a major toxicity of immune checkpoint inhibitors. Studies have reported that pre-existing autoimmunity increases the risk of irAEs, but it remains unknown which clinical factors are linked to auto-immune disorders in cancer patients.

8p vielonmusk 21-01-2022 24 0 Download

Multi-omics analysis of an immune-based prognostic predictor in non-small cell lung cancer

Inhibitors targeting immune checkpoints, such as PD-1/PD-L1 and CTLA-4, have prolonged survival in small groups of non-small cell lung cancer (NSCLC) patients, but biomarkers predictive of the response to the immune checkpoint inhibitors (ICIs) remain rare.

19p vielonmusk 21-01-2022 15 1 Download
Landscape of homologous recombination deficiencies in solid tumours: Analyses of two independent genomic datasets

DNA repair deficiencies are characteristic of cancer and homologous recombination deficiency (HRD) is the most common. HRD sensitizes tumour cells to PARP inhibitors so it is important to understand the landscape of HRD across diferent solid tumour types. Methods: Germline and somatic BRCA mu

13p vielonmusk 21-01-2022 17 2 Download
Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy

Immune checkpoint inhibitors (ICIs) are currently one of the most promising therapy options in the field of oncology. Although the first pivotal ICI trial results were published in 2011, few biomarkers exist to predict their therapy outcome. PD-L1 expression and tumor mutational burden (TMB) were proven to be sometimes-unre‑ liable biomarkers.

13p vielonmusk 21-01-2022 13 1 Download
Checkpoint inhibitors in metastatic gastric and GEJ cancer: A multi-institutional retrospective analysis of real-world data in a Western cohort

Safety and efficacy of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction (GEJ) cancer could be demonstrated in predominantly Asian cohorts, whereas data in Western patients outside of clinical trials are vastly missing.

10p vielonmusk 21-01-2022 16 0 Download
Modulation of chemoimmunotherapy efficacy in non-small cell lung cancer by sex and histology: A real-world, patient-level analysis

It has been postulated that patient’s sex impacts response to immunotherapy. Sex modulation of immunotherapy benefit, however, has not yet been explored using patient-level data, where potential confounder, as well as histologic type, can be accounted for. Here we investigated the association between sex and chemoimmunotherapy efficacy for non-small cell lung cancer (NSCLC) using a large, nation-wide dataset.

8p vielonmusk 21-01-2022 20 2 Download
Microsatellite instability is biased in Amsterdam II-defned Lynch-related cancer cases with family history but is rare in other cancers: A summary of 1000 analyses

Microsatellite instability (MSI) is a key marker for predicting the response of immune checkpoint inhibitors (ICIs) and for screening Lynch syndrome (LS). Aim: This study aimed to see the characteristics of cancers with high level of MSI (MSI-H) in genetic medicine and precision medicine.

12p vielonmusk 21-01-2022 10 0 Download